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Aims Sudden cardiac death (SCD) is the most common cause of death in children with hypertrophic cardiomyopathy
(HCM). The European Society of Cardiology (ESC) recommends consideration of an implantable cardioverter-
defibrillator (ICD) if two or more clinical risk factors (RFs) are present, but this approach to risk stratification has




Four hundred and eleven paediatric HCM patients were assessed for four clinical RFs in accordance with current ESC
recommendations: severe left ventricular hypertrophy, unexplained syncope, non-sustained ventricular tachycardia, and
family history of SCD. The primary endpoint was a composite outcome of SCD or an equivalent event (aborted cardiac
arrest, appropriate ICD therapy, or sustained ventricular tachycardia), defined as a major arrhythmic cardiac event
(MACE). Over a follow-up period of 2890 patient years (median 5.5 years), MACE occurred in 21 patients (7.5%) with
0 RFs, 19 (16.8%) with 1 RFs, and 3 (18.8%) with 2 or more RFs. Corresponding incidence rates were 1.13 [95% confi-
dence interval (CI) 0.7–1.73], 2.07 (95% CI 1.25–3.23), and 2.52 (95% CI 0.53–7.35) per 100 patient years at risk.
Patients with two or more RFs did not have a higher incidence of MACE (log-rank test P=0.34), with a positive and
negative predictive value of 19% and 90%, respectively. The C-statistic was 0.62 (95% CI 0.52–0.72) at 5 years.
...................................................................................................................................................................................................
Conclusions The incidence of MACE is higher for patients with increasing numbers of clinical RFs. However, the current ESC
guidelines have a low ability to discriminate between high- and low-risk individuals.
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Introduction
Hypertrophic cardiomyopathy (HCM) is the second commonest car-
diomyopathy occurring during childhood, with an estimated annual
incidence of 0.24–0.47 per 100 000 and prevalence of 2.7 per
100 000.1–3 Early reports suggested a very poor prognosis in child-
hood HCM,4 but more recent population-based and registry studies
have reported annual mortality rates between 1% and 2.5%.5–8 The
most common cause of mortality outside of infancy is sudden cardiac
death (SCD),6 making risk stratification for arrhythmic events one of
the cornerstones of the management of children with HCM. Despite
this, identification of those at high risk of SCD remains a challenge,
and there is currently a lack of evidence to support current risk strati-
fication algorithms for SCD in childhood HCM. The European
Society of Cardiology (ESC) guidelines9 recommend the use of four
clinical risk factors (RFs) to stratify risk in children with HCM: unex-
plained syncope, family history of SCD, extreme left ventricular hy-
pertrophy (LVH), and non-sustained ventricular tachycardia (NSVT)
on ambulatory electrocardiography (ECG) recordings. An implant-
able cardioverter-defibrillator (ICD) is recommended if two or more
clinical RFs are present. However, the efficacy of this approach to risk
stratification has not previously been validated. Although ICDs have
been shown to be effective at aborting malignant arrhythmias in chil-
dren with HCM,10,11 these younger patients experience a higher rate
of complications than adults,10 reinforcing the need to robustly iden-
tify individuals most likely to benefit from device implantation. This
study sought to perform the first validation of the 2014 ESC guide-
lines in a cohort of childhoodHCM from the UK.
Methods
Patients
Longitudinal clinical and outcome data were collected from a retrospec-
tive multi-centre cohort of children diagnosed with HCM in the UK be-
tween 1980 and 2017. Complete data were available from 13 out of the
14 UK specialist paediatric cardiac centres. Patients aged 16 years or
younger meeting the diagnostic criteria for HCM were eligible for inclu-
sion. This included patients with phenocopies of sarcomeric HCM (e.g.
RASopathies, inborn errors of metabolism, or neuromuscular diseases).
The diagnosis of HCM was made in the presence of left ventricular wall
thickness >2 SD above the body surface area (BSA)-corrected popula-
tion mean (z-score >_þ2), which could not be solely explained by
abnormal loading conditions.9 Data on the clinical presentation and sur-
vival of the entire cohort have been recently published.8 In the present
study, patients with a history of sustained ventricular arrhythmias or
aborted SCD were excluded from analysis, as they meet criteria for sec-
ondary prevention ICD implantation. Eligible patients were identified by
the principle investigator at each site using multiple sources, including
medical databases and echocardiography log books. Where available, the
reasons for diagnosis included family screening, symptoms, and incidental
findings of abnormal ECG or heart murmur.
Data collection
A single researcher (G.N.) visited each site to assist with data collection
and confirm diagnostic classification. Anonymized, non-invasive clinical
data were collected from baseline evaluation, including demographics,
aetiology, symptoms, family history, resting and ambulatory ECG, two-di-
mensional Doppler and colour transthoracic echocardiography, and de-
vice interrogation of arrhythmic events. Aetiology was classified as non-
syndromic in the absence of a diagnosis of a RASopathy syndrome
(Noonan or other malformation syndrome), neuromuscular disease (in-
cluding Friedreich’s ataxia), or inborn error of metabolism.
In accordance with the 2014 ESC guidelines,9 RFs for an arrhythmic
event were assessed at baseline and comprised: NSVT—defined as three
or more consecutive ventricular beats at a rate of >120 beats/min with a
duration of <30 s on ambulatory ECG recordings; severe LVH—defined
as a maximal left ventricular wall thickness (MLVWT) >_30mm or >_6 SD
above the population mean for BSA; unexplained syncope—defined as a
transient loss of consciousness with no identifiable cause; and family his-
tory of SCD—defined as SCD in a first degree relative <40 years of age
or SCD in a relative with confirmed HCM at any age.
Outcomes and follow-up
All patients were routinely evaluated every 6–12months up to 1
October 2017. The primary patient outcome, taken from last clinic ap-
pointment, was a composite outcome of SCD or an equivalent event
(aborted cardiac arrest, appropriate ICD therapy, or sustained ventricular
tachycardia associated with haemodynamic compromise or syncope), de-
fined as a major arrhythmic cardiac event (MACE).
Statistical analysis
Body surface area was calculated from height and weight.12 Left ventricu-
lar wall thickness measurements are expressed in millimetres and as
z-scores relative to the distribution of measurements vs. BSA in normal
children, using previously published normal values.13 Normally distrib-
uted continuous variables are described as mean± standard deviation.
Skewed data are described as median [interquartile range (IQR)].
Kaplan–Meier survival curves were used to obtain estimates of the inci-
dence of a MACE and Poisson exact confidence intervals calculated. Due
to small patient numbers, patients with two or more RFs were combined
and group differences in survival were assessed using the log-rank test.
A significance level of 0.05 was used for all comparisons.
For the purpose of analysis, patients with syndromic HCM were ex-
cluded as they are a heterogeneous population with variable long-term
outcomes, which are partly determined by the underlying aetiology.
However, as the ESC guidelines do not specifically exclude patients with
non-sarcomeric disease, separate analyses were also performed including
these patients (Supplementary material online) (Figure 1). The ESC guide-
lines assign each clinical RF equal weight and the overall clinical risk profile
is calculated as the sum of RFs present. For the purpose of assessing the
discriminatory ability of the ESC algorithm, missing data for RFs were
coded as absent to reflect the use of the guideline in clinical practice.14 As
this may be a source of bias, a complete case analysis was also performed
What’s new?
• The incidence of an arrhythmic event increases with additional
clinical risk factors, however, the current European Society of
Cardiology (ESC) 2014 guideline for risk stratification in child-
hood hypertrophic cardiomyopathy (HCM) has a low ability
to discriminate between high- and low-risk individuals.
• The positive predictive value of the ESC treatment threshold
is low, leading to unnecessary implantable cardioverter-defibril-
lator implantation in many patients.
• Large-scale, multi-centre, collaborative approaches to risk
stratification in childhood HCM are needed to develop robust
risk stratification algorithms.
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(Supplementary material online). The RF profile was considered as a con-
tinuous score ranging from 0 (when all RFs were absent) to 4 (when all
RFs were present) and the C-statistic at 1 and 5 years was estimated. The
receiver operating characteristic curve was constructed by plotting the
sensitivity against (1" specificity) for each possible prognostic value (e.g.
>_0, >_1, >_2, >_3, or >_4 RFs) and then calculating the area under the curve.
The positive predictive value (PPV) of a particular RF profile was calcu-
lated by dividing (sensitivity# prevalence) by ((sensitivity# prevalen-
ce)þ (1" specificity)# (1" prevalence)) and expressed as a
percentage. The negative predictive value (NPV) was calculated by divid-
ing (specificity# (1" prevalence)) by ((1" sensitivity# prevalence)þ
(specificity# (1" prevalence)) and expressed as a percentage. Statistical
analysis was performed using StataCorp. 2015. Stata Statistical Software:
Release 14. College Station, TX, USA: StataCorp LP.
Ethics
Ethical committee approval was obtained at each participating site. The
study complies with the principles of Good Clinical Practice and the
Declaration of Helsinki.
Results
From the total cohort of 687 patients,8 411 patients had non-
syndromic HCM, diagnosed aged 16 years or younger, and without a
previous history of sustained ventricular tachycardia or aborted car-
diac arrest (Figure 1). Baseline clinical characteristics are shown in
Table 1. Median age at diagnosis was 10 years (IQR 3–13); 60 patients
(14.6%) presented under the age of 1 year. Pathogenic mutations in
sarcomeric protein genes were reported in 94 patients (23%). One
hundred and ten patients (26.8%) had an ICD implanted during
follow-up for primary prevention [n=99 (90%)] and secondary
prevention [11 (10%)]. Of those with a secondary prevention device,
the indication for ICD implantation was an aborted SCD in nine
patients and sustained VT on ambulatory ECGmonitoring in two.
Prevalence of European Society of
Cardiology clinical risk factors
The prevalence at baseline of each of the four major clinical RFs de-
scribed in the 2014 ESC guidelines is shown in Table 2. Two hundred
and eighty-two patients (68.7%) had no traditional clinical RFs, 113
(27.5%) had a single clinical RF, 14 (3.4%) had two clinical RFs, and
two patients (0.5%) had three clinical RFs. No patients had all four
clinical RFs. Complete data for all clinical RFs were available for 295
patients (71.8%), data were missing for one or two RFs in 111
patients (27%) and 5 patients (1.2%), respectively.
Arrhythmic events and clinical risk factor
profile
Median length of follow-up was 5.5 years (IQR 2.4–10.6). Over a total
follow-up period of 2890 patient years, 43 patients had a MACE with
an event rate of 1.5 per 100 patient years at risk. The MACE was
SCD in 17 (4.1%); aborted cardiac arrest in 9 (2.2%); appropriate
ICD discharge in 12 (2.9); and sustained VT associated with haemo-
dynamic compromise in 5 (1.2%). Sustained VT was documented on
ICD download (n=3) or an implantable ambulatory ECG device
(n=2).
A MACE occurred in 21 patients (7.5%) with no clinical RFs; 19
patients (16.8%) with one clinical RF; and 3 patients (18.8%) with two
or more clinical RFs (Table 3). Event-free survival at 5 years for
patients with 0, 1, or >_2 clinical RFs was 93.8% [95% confidence





















Figure 1 Flow chart showing aetiology of HCM in whole cohort. HCM, hypertrophic cardiomyopathy; IEM, inborn error of metabolism; NMD,
neuromuscular disorder; SCD, sudden cardiac death.
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(56.4–96.5%), respectively (Figure 2). The corresponding incidence
rates are shown in Table 3.
Of the 113 patients with a single ESC RF, 49 (44%) had severe
LVH; 22 (20%) unexplained syncope; 40 (35%) a family history of
SCD; and 2 (2%) NSVT. The incidence of MACE in patients with a
single clinical RF is shown in Table 4 . The PPV and NPV of a single clin-
ical RF for a MACE was 17.1% and 92.6%, respectively.
Patients classified as ‘high risk’ according to the ESC guidelines (>_2
clinical RFs) did not have a higher incidence of MACE compared to
‘low risk’ patients (log-rank test P=0.34) (Figure 3).
Discrimination performance of the 2014
European Society of Cardiology risk
stratification guidelines
The C-statistic, which represents the probability of correctly distin-
guishing between high and low risk patients using the 2014 ESC clini-
cal risk profile, was 0.58 (95% CI 0.31–0.86) at 1 year and 0.62 (95%
CI 0.52–0.72) at 5 years (Figure 4 ). The PPV and NPV of the 2014 ESC
treatment thresholds for primary prevention ICD implantation (>_2
clinical RFs) at 5-year follow-up and end of follow-up were 12.5%/
93.9% and 18.8/89.9%, respectively. A complete case analysis
(n=295) did not improve the discrimination performance of the
guideline with a PPV and NPV of 23.1% and 89%, respectively, and C-
statistic of 0.63 (95% CI 0.54–0.72) (Supplementary material online).
A sensitivity analysis including syndromic patients (n=663) did not
improve the discrimination performance of the guideline with a PPV
and NPV of 23.5% and 92.9%, respectively, with a c-statistic of 0.63
(95% CI 0.557–0.703).
Discussion
This study is the first external validation of the current ESC guidelines
for risk stratification in childhood HCM. We show that the current
guidelines have only a modest ability to discriminate between patients
with non-syndromic HCM at a low or high risk of an arrhythmic
event, with a C-statistic of 0.62 at 5 years.
Risk factors for sudden cardiac death in
childhood hypertrophic cardiomyopathy
The majority of patients (69%) in this cohort had none of the tradi-
tional clinical RFs for SCD historically used for risk stratification in
adults, and only a small number of patients met the ESC threshold for
ICD implantation (16 patients, 3.9%). However, the overall rate of ar-
rhythmic events was higher in childhood disease compared to adult-
hood (1.1 vs. 0.8%), particularly for those with non-syndromic
disease (1.5 vs. 0.8%). This suggests that additional, or alternative, clin-
ical RFs for SCD are important in childhood onset disease. Indeed, al-
though a large number of potential RFs for SCD in childhood HCM
have been reported in the literature, the lack of consistent definitions
and sufficiently large, suitably designed population studies means that
the evidence for individual RFs, including those endorsed by the ESC
guidelines, is not robust. A meta-analysis of published clinical RFs for
SCD in childhood HCM15 identified four clinical RFs that are likely to
be important for risk stratification in children: previous aborted car-
diac arrest, NSVT, extreme LVH, and unexplained syncope.
Importantly, a family history of SCD, which is included in the ESC
guidelines, was not identified as a major RF as it was only associated
with SCD in one11 out of seven included studies. Possible explana-
tions for this include: a higher prevalence of de novo mutations in
childhood HCM; insufficient reporting of family history in included
Table 1 Clinical characteristics of non-syndromic
study population at baseline evaluation
Age (years), median (IQR) 10 (3–13)
Infant 60 (14.6%)
1–<6 years 73 (17.8%)
6–<12 years 113 (27.5%)
12–<16 years 165 (40.1%)
Male gender 271 (66%)
NYHA III/IV (n=410) 15 (3.7%)
Maximal wall thickness at baseline (mm), mean (range)
(n=398)
17.0 (6–48)
Left ventricular outflow tract obstruction (>30mmHg)
(n=374)
104 (27.8%)




n=411 unless otherwise indicated.
ICD, implantable cardioverter-defibrillator; IQR, interquartile range; NYHA, New
York Heart Association.
.................................................................................................
Table 2 Prevalence of ESC clinical risk factors at
baseline
Non-syndromic only,
n (%) (n5 411)
MWT >_30mm or z-score >_6 63/398 (15.8)
NSVT 5/307 (1.6)
Unexplained syncope 30/409 (7.3)
Family history of SCD 49/409 (12)
ESC, European Society of Cardiology; MWT, maximal wall thickness; NSVT, non-
sustained ventricular tachycardia; SCD, sudden cardiac death.
...................................................................
.................................................................................................
Table 3 Incidence of a MACE by clinical risk profile




MACE, n (%) Incidence rate/100
patient years (95% CI)
0 21 (7.5) 1.13 (0.70–1.73)
1 19 (16.8) 2.07 (1.25–3.23)
>_2 3 (18.8) 2.52 (0.53–7.35)
CI, Poisson exact 95% confidence interval; MACE, major arrhythmic cardiac
event.
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studies; or lack of adjustment for family linkage. In addition, although
LVH has been shown to be associated with SCD in several studies,
only one reported a significantly increased risk associated with an
MLVWT>_30mmor >_6 SD above populationmean for BSA,16 which
is the definition endorsed by the guidelines. A systematic assessment
of clinical RFs in childhood HCM is therefore required to identify the
most useful clinical features to predict risk.
Discriminatory power of current
guidelines for risk stratification in
childhood
As each traditional clinical RF included in the ESC guidelines is a
marker of more severe disease, it is perhaps not surprising that the
risk of an event increased incrementally with summative RFs.
However, the incidence rate did not significantly differ between those
classified by the guideline as high risk or low risk, meaning that the
ability of the guideline threshold to distinguish between those
patients at high and low risk was limited. Although the arrhythmic in-
cidence rate was lowest for patients with no clinical RFs, the majority
of events (63%) occurred in this low-risk group. Furthermore, the
low PPV (18.8%) means that the majority of patients in whom an ICD
is recommended will not experience an event but will be exposed to
the potential complications associated with ICD implantation. In this
cohort of 110 patients with an ICD, only 11% had an appropriate dis-
charge to treat a malignant arrhythmia. The low number of patients
receiving appropriate therapy likely highlights the difficulties in identi-
fying patients at increased risk. Indeed, over half (56%) of MACE oc-
curred in patients not judged to be at increased risk by clinicians who
therefore did not undergo ICD implantation. Application of the ESC
clinical guideline did not improve patient identificationwith 93% of ar-
rhythmic events occurring in patients with 0 or 1 clinical RFs. This is a
particular problem for childhood HCM, as it has been shown that
younger patients are at higher risk of ICD-related complications10
and will also be exposed to these risks for a longer period of time.
The availability of subcutaneous ICDs, which avoid the need for intra-
vascular or intracardiac leads, may reduce the complication burden in
this group of patients.
The current guidelines do not specifically exclude patients with
syndromic HCM (RASopathy syndrome, neuromuscular disease, or
inborn error of metabolism) and excluding these patients from the
analysis did not improve the discriminatory power of the guidelines.
Of note, current North American guidelines17 make use of the same
....................................................................................................................................................................................................................
Table 4 Incidence of a MACE in patients with non-syndromic HCM and a single risk factor
N (%) Length of FU (years),
median (IQR)
MACE, n (%) Incidence rate/100
patient years (95% CI)
5-Year cumulative
incidence of MACE
MWT >_30mm or z-score >_6 49 (44%) 6.3 (3.08–12) 9 (16%) 1.9 (0.83–3.80) 9.3 (3.57–22.9)
Unexplained syncope 22 (20%) 4.1 (1.83–9.42 6 (27%) 4.2 (1.53–9.1) 27.6 (12.2–54.9)
Family history of SCD 40 (34%) 7.1 (2.5–12.8) 5 (12.5%) 1.5 (0.5–3.59) 8.8 (2.9–25.1)
NSVT 2 (2%) 17.9 (15.33–20.58) 0
n=113.
CI, Poisson exact 95% confidence interval; FU: follow-up; HCM, hypertrophic cardiomyopathy; IQR, interquartile range; MACE, major arrhythmic cardiac event; MWT, maximal
wall thickness; NSVT, non-sustained ventricular tachycardia; SCD, sudden cardiac death.
Figure 2 Kaplan–Meier survival curve showing event-free survival
from MACE over follow-up for different clinical risk factor profiles.
Log-rank test 0.8993. MACE, major arrhythmic cardiac event.
Figure 3 Cumulative incidence of MACE for patients at low (<2
clinical risk factors) or high (>_2 clinical risk factors) risk for SCD
according to ESC treatment threshold. Log-rank test P=0.34. ESC,
European Society of Cardiology; MACE, major arrhythmic cardiac
event; SCD, sudden cardiac death.
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traditional RFs (unexplained syncope, family history of SCD, and ex-
treme LVH), although recommend that an ICD is considered reason-
able in the presence of a single RF only. The presence of a single RF
was associated with an increased incidence of an arrhythmic event
(17% within 5 years), but the discriminatory power of this threshold
for ICD was similarly poor (PPV 17.1%; NPV 92.6%). The small num-
ber of patients with a single RF prevents a meaningful comparison be-
tween the risk of MACE for each individual RF as the calculated
confidence intervals are wide (Table 4 ). However, the high NPV of
the ESC treatment threshold (89.9%) supports the notion that
patients with 0 or 1 clinical RF are at a low risk for ventricular
arrhythmias and can be reassured. Large multi-centre collaborative
studies are required to investigate the role of individual RFs in child-
hood HCM.
Future directions
Childhood HCM is recognized to be a heterogeneous disease.5,6 In
our UK cohort, 37% of patients had either a RASopathy syndrome,
neuromuscular disease, or inborn error of metabolism, and age of di-
agnosis ranged from 1 to 16 years of age.8 Current guidelines do not
account for this heterogeneity, providing relative risks for an arrhyth-
mic event for non-homogenous groups rather than individualized
estimates. This approach to risk stratification necessarily converts
continuous variables [e.g. maximal wall thickness (MWT)] into a bi-
nary variable (e.g. MWT<30mm or MWT>_ 30mm), the clinical va-
lidity of which, particularly during childhood which is a period of
significant somatic growth, may be questioned. In agreement with
our findings, this approach to risk stratification has been shown to
have a low predictive power in adult HCM patients, with unnecessary
ICD implantation in a large number of patients.14 As a result, more
recently, the ESC endorsed the use of an SCD risk prediction model
(HCM Risk-SCD) which provides an individualized estimate of 5-year
SCD risk.18 External validation of this approach to risk stratification
has shown that this model has an improved discriminatory power (c-
index 0.7),19 although other studies have reported that it underesti-
mates risk.20 Nonetheless, it is not currently validated for use in
patients under the age of 16 years of age. The ability to provide an
individualized estimate for the risk for SCD in childhood HCMwould
be of significant benefit in clinical practice.
Limitations
This study is limited by inherent problems of retrospective studies, in
particular missing or incomplete data. Although the classification of
missing RF data as absent is a source of potential bias, this reflects real
world practice where absence of a RF is often taken to mean absence
of risk. This approach to analysis replicates that used by other retro-
spective validation studies in adult HCM (Ref.14) in which only 78%
of patients had a complete RF dataset. The higher percentage of miss-
ing data in our cohort likely reflects difficulties in obtaining certain
investigations (e.g. ambulatory ECGs) in very young patients but may
have resulted in an under-estimation of the prevalence of clinical RFs
(particularly arrhythmic events). Limiting data analysis to those
patients with complete data did not alter the overall results of the
study and did not improve the discriminatory performance of the
guideline (Supplementary material online).
As childhood HCM is a rare disease and SCD a relatively rare out-
come, despite this study containing one of the largest populations of
childhood HCM to date, there were a small number of events and
small number of patients classified as ‘high risk’ according to the ESC
guidelines. This reduced our power to detect statistically significant
differences and, as a result, the reported confidence intervals are
wide. The relatively short mean follow-up time of 5.5 years (range
6 months–25 years) could partly explain the low number of events.
However, it is important to note that the current guidelines do not
provide an estimate of risk at a particular time point. Relatively little is
known about the sample size requirements for external validation of
prediction models, although a sample containing at least 100 events
and 100 non-events has been suggested.21 Using published rates of
arrhythmic events in childhood HCM of 1.5/100 patient years8 with a
median follow-up of 5 years, this would require over 1300 patients
assuming no dropout during the 5-year follow-up period. Such a sam-
ple size would be challenging to achieve for a rare condition with a
reported prevalence of childhood HCM below 3/100000.
Furthermore, this study only includes RF assessment findings from
A B
Figure 4 Receiver operating characteristic curves for the ESC guidelines at (A) 1 year and (B ) 5 years, respectively. ESC, European Society of
Cardiology; ROC: Receiver operating characteristic.
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the initial clinical evaluation, in keeping with current ESC recommen-
dations9 and previous adult studies,14 and does not assess disease
progression and potential changing risk profiles with time. Large-
scale, prospective, multi-centre studies, or registries with standard-
ized investigation protocols are needed to overcome and address
these challenges in risk stratification for childhood HCM.
In this cohort, only 23% of non-syndromic patients had a con-
firmed pathogenic mutation in a cardiac sarcomere protein gene.
This is almost certainly an underestimate of the true prevalence as
previous studies have shown that most cases of HCM are caused by
sarcomeric mutations, even in young children.22 This finding likely
reflects a lack of consistent and systematic genetic testing in this co-
hort. Although the long period of recruitment may result in changes
in assessment and therapies influencing the findings in this study, we
have previously shown no era effect in survival in this cohort.8
Conclusions
This study is the first validation of the 2014 ESC risk stratification
guidelines for childhood HCM. The results suggest that the current
guidelines have a limited ability to distinguish between high- and low-
risk patients. Although the incidence of an arrhythmic event increases
with additional RFs, the PPV of the treatment threshold is low with
unnecessary ICD implantation in many patients. Large-scale interna-
tional collaborative studies are required to overcome the challenges
of small patient numbers inherent to rare diseases.
Supplementary material
Supplementary material is available at Europace online.
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